The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

Wed, 22nd Dec 2021 11:28

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Genedrive PLC, up 27% at 45.75p, 12-month range 15.75p-47.84p. The molecular diagnostics firm has filed for approval to sell its Covid-19 test kit in the UK, as part of new Coronavirus Test Device Approvals regulations which came into effect last month. The company's kit is a rapid molecular diagnostic test that delivers positive results as quickly as 7.5 minutes and negative results at 17 minutes.

----------

Avacta Group PLC, up 23% at 129.70p, 12-month range 97.00p-291.80p. The biotechnology firm says its AffiDX Covid-19 antigen lateral flow test has received a CE mark for consumer self-test use in the UK and EU. The tests will be marketed by Medusa Healthcare under the brand name 'MeduFlow'. Medusa Healthcare is a subsidiary of Medusa 19 Ltd, a Manchester-based scientific equipment supplier.

----------

D4T4 Solutions PLC, up 13% at 322.00p, 12-month range 241.11p-410.00p. The data solutions provider says contract wins will contribute significant revenue in the current year. These include a multi-year contract extension and upsell to an unnamed US-based financial services company, and a license renewal and conversion to annual recurring revenue model by a bank based in Europe. Says contract wins add over GBP3 million per annum to annual recurring revenue as well as over GBP9 million to the current year's revenue.

----------

AIM - LOSERS

----------

Bluerock Diamonds PLC, down 16% at 25.14p, 12-month range 25.14p-67.00p. Shares hit 12-month low as diamond producer says operations at its Kareevlei mine in South Africa have been restricted. Says there has been 24 reported cases of Covid-19 amongst the Kareevlei workforce and 50% of the employees have not reported for work due to them having contact with affected employees. As such, operations at the site have been restricted until January 3. "The closure comes at a very unwelcome time as both lines are now operational, and management has been focusing on ramping up production," says Chair Mike Houston.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
5 Apr 2023 12:51

Avacta doses first patient in higher-dose oncology cohort

(Sharecast News) - Life sciences company Avacta Group announced that it had dosed the first patient in the fifth cohort of the first-in-human phase one trial of its innovative oncology drug 'AVA6000' on Wednesday.

Read more
5 Apr 2023 12:12

Avacta doses first patient in fifth cohort of AVA6000 phase 1 study

(Alliance News) - Avacta Group PLC on Wednesday said the first patient has been dosed in the fifth cohort of the first-in-human phase 1 trial of AVA6000, a novel form of doxorubicin designed to improve its safety and therapeutic index.

Read more
27 Mar 2023 13:44

Avacta to present tumour medicine data at cancer research meeting

(Sharecast News) - Life science company Avacta Group announced on Monday that it will present a poster on its novel 'preCISION' medicine, 'AVA3996', at the American Association for Cancer Research (AACR) 2023 annual meeting in Florida on 16 April.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
13 Mar 2023 10:08

Avacta has 'no relationship' with failed tech-focussed bank

(Sharecast News) - Life science company Avacta reassured the market on Monday, following the collapse of technology and science-focussed Silicon Valley Bank last week.

Read more
17 Jan 2023 17:16

Avacta reports positive progress in chemotherapy trial

(Sharecast News) - Oncology drug and diagnostics developer Avacta Group said in an update on Tuesday that 'AVA6000' was continuing to show a "very favourable" safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase-one clinical trial.

Read more
17 Jan 2023 16:23

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
8 Nov 2022 13:51

Avacta raises GBP64 million to finance Launch Diagnostics purchase

(Alliance News) - Avacta Group PLC on Tuesday closed its GBP2.0 million open offer of shares, bringing its total fundraise to GBP64.0 million.

Read more
18 Oct 2022 12:40

Avacta plans to raise GBP62 million; buys Launch Diagnostics

(Alliance News) - Avacta Group PLC on Tuesday announced a GBP62.0 million fundraise, which will be partially used to finance its acquisition of Launch Diagnostics Holdings Ltd for up GBP37 million.

Read more
18 Oct 2022 11:12

Avacta buying Launch Diagnostics for initial £24m

(Sharecast News) - Clinical-stage oncology drug company Avacta has conditionally agreed to acquire Launch Diagnostics, it announced on Tuesday, for an upfront cash consideration of £24m on a debt-free, cash-free basis.

Read more
29 Sep 2022 11:56

Avacta losses narrow as it progresses clinical programmes

(Sharecast News) - Clinical-stage oncology drug developer Avacta reported first-half revenue of £5.5m on Thursday, up from £1.5m year-on-year and from £2.9m for the full 2021 period.

Read more
29 Sep 2022 11:30

Avacta narrows loss, multiplies revenue thanks to Therapeutics divison

(Alliance News) - Avacta Group PLC on Thursday reported a narrowed interim loss as it multiplied its revenue significantly thanks to a strong performance from its Therapeutics division.

Read more
5 Sep 2022 11:07

AIM WINNERS & LOSERS: Avacta gets approval; Jubilee's Roan at capacity

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
5 Sep 2022 10:10

Avacta shares up as drug approved for soft tissue sarcoma treatment

(Alliance News) - Avacta Group PLC on Monday said it received approval for its AVA6000 for treatment of soft tissue sarcoma.

Read more
5 Sep 2022 07:16

Avacta's soft tissue sarcoma treatment gets FDA orphan drug designation

(Sharecast News) - Biotechnology company Avacta Group said on Monday that its soft tissue sarcoma treatment has been granted orphan drug designation by the US Food and Drug Administration.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.